An interventional study of Home Pelvic Floor Trainer in Pelvic Pain, Pelvic Floor Dysfunction and Voiding Dysfunction, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Pelvic Pain with a site in United States — 37 open to participants now, 40 under way, 1 of them phase 3. Pelvic Pain · United States.
Among the 152 studies in Pelvic Pain with a site in United States, this one is the 18th largest by planned enrollment of the 124 interventional ones that give a count, is one of 15 that started in 2026, is one of 72 with no phase, reaches primary completion later than 32 of the 39 other live ones, and was the 136th registered.
377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.
Browse Pelvic Pain studies →37 of the 152 studies in Pelvic Pain with a site in United States are open now. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 18–45 · Women only
SWIMS America Corp. · Sites in United States
Ages 18+ · Women only
Milton S. Hershey Medical Center · Sites in United States
Ages 18–45
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
SoLa Pelvic Therapy · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 23 · Phase 3 9 · Phase 4 13
First in 1998; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 60 across 278 interventional studies indexed under Pelvic Pain.
Median enrollment 50 across the 124 interventional studies, 104 across the 28 observational. Of the 96 that completed or were terminated, 35 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 152 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 1 study filed under Pelvic Pain — fewer than ten, so there is no comparison to draw.
16 of the studies in Pelvic Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06110065University of ArizonaCT-guided Pudendal Nerve Cryoneurolysis for Palliation of Malignancy-induced Pelvic Pain | 2026-11 |
| NCT05354869University of California, Los AngelesTransvaginal Electrical Stimulation for Myofascial Pelvic Pain | 2026-12 |
| NCT03794466University of Kansas Medical CenterQuantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization | 2026-12-31 |
| NCT06083597Weill Medical College of Cornell UniversityDevelopment of a Patient-reported Outcome Measure for Women With Chronic Pelvic Pain | 2026-12-31 |
| NCT06611501Boston Children's HospitalGlycemic Regulation as Endometriosis Adjunct Treatment | 2027-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 152 studies in Pelvic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will gauge the efficacy of a home biofeedback treatment device for pelvic floor dysfunction/voiding dysfunction and pelvic pain. Investigators will test the utility of this device as a treatment alternative and/or temporary treatment for a patient's symptoms prior to or perhaps in lieu of their physical therapy appointment.
This study aims to determine if a special device can help children with pelvic floor problems. The pelvic floor issues under investigation include difficulty controlling urination and ongoing pain in the lower belly. The study will explore whether the device helps children gain better control over urination.
It will also investigate if the device contributes to the reduction of pelvic pain experienced by children. Furthermore, the study will analyze if the device leads to improvement in how the body functions during urination. The consistency with which children use the device and adhere to instructions will be monitored. Finally, the study includes an assessment of whether children find the device acceptable for use.
The criteria were revised on the registry on Oct 20, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: This would include patients who begin physical therapy for their pelvic floor outside of the study while enrolled in the study.
- All patients with the following conditions: severe developmental delay such as CP or wheelchair bound, cannot eat by mouth, mechanical ventilation dependence, etc.
Patients with voiding dysfunction only and no pelvic pain symptoms will use the home pelvic floor trainer daily for 2 months.
Device: Home Pelvic Floor Trainer
Patients with pelvic pain with or without voiding dysfunction symptoms will use the home pelvic floor trainer daily for 2 months.
Device: Home Pelvic Floor Trainer
The intervention utilizes a perineometer device with biofeedback features. This device employs external electrodes to measure pelvic floor muscle strength. It then provides real-time feedback through a smartphone application during exercise sessions. The application uses gamification to engage users and track progress. Patients can choose between two games: a bird game or a space-themed game. In the bird game, patients activate their pelvic floor muscles to make the bird fly upward. In the space game, pelvic floor contractions fire a laser or activate a shield. A visual bar displays the strength of pelvic floor contractions. Games are designed to be played for 5 minutes daily, 7 days a week, with increasing difficulty as the user progresses through levels.
Dysfunctional Voiding Symptom Scale (30 point scale)
This survey will be given to all participants and is the primary outcome of the DV group. This will be attained before the start of treatment, at 4-week mark, and at 8-week visit. The DVSS is a 30 point scale with higher scores representing more severe voiding dysfunction symptoms. Males with score greater than 9 points are considered to have voiding dysfunction, and females with score greater than 6 are considered to have voiding dysfunction.
Time frame: 0 weeks baseline, 4 weeks, and 8 weeks patients will take the DVSS survey
McGill Pain Scale (Short Form - points scale)
This survey will be given to all participants and is the primary outcome of the Pelvic Pain group. This will be attained before the start of treatment, at 4-week mark, and 8-week visit. Total of 22 items with 0-10 numerical response options, 0 being no pain and the higher score representing more pain)
Time frame: 0 weeks baseline, 4 weeks, and 8 weeks patients will take the McGill Pain Scale Short Form survey
Post-Void Residual Volume (mL)
PVR volume \> 10% normal will be considered elevated PVR. This will be attained from all participants at an initial baseline urology visit as part of standard of care, and the 8-week in-person visit.
Time frame: 0 weeks baseline, 8 weeks in-person visits investigators will attain PVR
Uroflowmetry
Uroflowmetry parameters will be assessed at the initial and 8-week visits. These parameters include: A normal, bell-shaped curve. A tower flow curve, suggesting detrusor overactivity. A staccato flow curve, suggesting external sphincter activity. An intermittent or interrupted flow curve, suggesting underactive detrusor or dysfunctional voiding. A plateau shape curve, suggesting bladder outlet obstruction
Time frame: Investigators will attain uroflowmetry at the same time as the PVR measurement, at initial baseline (0 weeks) and last (8 weeks) in-person visits.
Plan to share: No
Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.
Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 24 months is above that.
Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jun 2025 → Nov 2026, primary completion Jan 2027 → Nov 2028 and completion Jan 2027 → Nov 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →